Primary Care Update 2024

Section 1: Best Practices in Prescribing Opioids: A regulatory perspective .

• Describe evolving opioid prescribing and regulatory practices in the United States.

  Discuss recently released opioid prescribing guidelines, highlighting the relevance to outpatient treatment of pain.

  Describe best practices and patient care resources for managing patients with acute or chronic nonmalignant pain, highlighting guidance from a regulatory per-spective. Regulatory Cases with Opioid Medications

  Apply best practices in the prescribing of opioids and other controlled substances.

  Discuss key physiologic and common pathophysiologic changes of aging that impact drug therapy .

Session 2: Addiction as a Brain Disease:

• Examine the neurobiological responses to substances of abuse,.

• Describe howyour brain responds to drugs.

  Explore how addiction affects the brain.

  Examine behavioral changes in addiction.

Session 3: Screening, Brief Intervention, and Referral to Treatment (SBIRT):

• Explore SBIRT (Screening, Brief Intervention, and Referral to Treatment) as a routine part of care in all healthcare settings.

• Review guidelines for providing, billing, and coding for SBIRT services. Case Study in Acute Post-Operative Pain and Diversion Control :

• Integrate best practicesor appropriate prescribing of controlled substances, screening for substance use disorders, and diversion control.

Session 1: Avoiding Drug Injury in Older Adults: A focus on controlled substances

• Discuss key physiologic and common pathophysiologic changes of aging that impact drug therapy.

• Case Study in Identifying and Avoiding Drug Injury in Older Adults

• Apply age-sensitive principles for medication dosing and management to clinical scenarios.

Session 2: Optimizing Drug Therapy and Avoiding Drug Injury in Older Adults

• List nine key questions useful for identifying and managing inappropriate polypharmacy (i.e. unnecessary medication use) in older adults.

• Discuss high risk drug-drug and drug-dietary supplement interactions commonly encountered in primary care, including best practices in identifying and managing related toxicities.

• Case Study in Optimizing Drug Therapy in Older Adults

• Apply practical tools to screen and appropriately manage complex drug regimens among older adults with or at-risk for drug injury.

Session 3: Drug Therapy for Depression

• Discuss pharmacologic management options within clinical cases of adults with depression.

• Relate physiologic and pathophysiologic alternations of brain neurochemistry to symptoms of depression, including the genetic link and molecular basis of injury.

• Apply clinical practice guidelines for antidepressant therapies.

• Describe key parameters for medications used to treat mechanism, safety, tolerability, efficacy, cost, and simplicity of use.

• Case Study in Diabetes and Depression-diagnosis and treatment

• Apply practical tools to screen diabetic patients for depression and appropriately manage depression in diabetic patients.

Session 4: Medical Management of Common Substance Use Disorders

• Explore evidence-based treatment approaches for substance use disorders.

• Discuss strategies to fully engage patients and their families in the process, including shared decision-making and building trust.

• Gain insights into pharmacotherapeutic treatments, including their mechanisms of action, risks, and benefits as well as relevant psychosocial and psychotherapeutic interventions.

• Explain recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with hypertension, hypercholesterolemia, chronic coronary disease, peripheral arterial disease, heart failure, and atrial fibrillation.

• Identify how future cardiovascular risk is estimated in primary prevention patients using the Pooled Cohort Equations and PREVENT calculator.

• List recommendations from the ACC Expert Consensus Decision Pathway for nonstatins and treatment of hypertriglyceridemia

• List guideline recommendations supporting the use of antiplatelet therapy for primary prevention patients.

• Summarize the evidence-based CV risk reduction benefits of medications used to treat overweight and obese patients.

• Recognize the role of colchicine in the prevention of CV events.

• Select treatment plans that reduce the risk of cardiovascular disease.